Lee Hyang-Mi
College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.
Biomol Ther (Seoul). 2022 Jul 1;30(4):299-308. doi: 10.4062/biomolther.2021.180. Epub 2022 Mar 10.
T cells are attractive targets for the development of immunotherapy to treat cancer due to their biological features, capacity of cytotoxicity, and antigen-specific binding of receptors. Novel strategies that can modulate T cell functions or receptor reactivity provide effective therapies, including checkpoint inhibitor, bispecific antibody, and adoptive transfer of T cells transduced with tumor antigen-specific receptors. T cell-based therapies have presented successful pre-clinical/clinical outcomes despite their common immune-related adverse effects. Ongoing studies will allow us to advance current T cell therapies and develop innovative personalized T cell therapies. This review summarizes immunotherapeutic approaches with a focus on T cells. Anti-cancer T cell therapies are also discussed regarding their biological perspectives, efficacy, toxicity, challenges, and opportunities.
由于T细胞的生物学特性、细胞毒性能力以及受体的抗原特异性结合，它们是开发癌症免疫疗法的有吸引力的靶点。能够调节T细胞功能或受体反应性的新策略提供了有效的治疗方法，包括检查点抑制剂、双特异性抗体以及转导了肿瘤抗原特异性受体的T细胞的过继转移。基于T细胞的疗法尽管存在常见的免疫相关不良反应，但已呈现出成功的临床前/临床结果。正在进行的研究将使我们能够推进当前的T细胞疗法，并开发创新的个性化T细胞疗法。本综述总结了以T细胞为重点的免疫治疗方法。还从生物学角度、疗效、毒性、挑战和机遇等方面讨论了抗癌T细胞疗法。
